world1 outlet covering this

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

First publishedJun 16, 12:41 UTC

Last updatedJul 12, 12:32 UTC · 13m ago

↻

each logo = when that outlet publishedlast updated on Braven

Story signals

How strong is this topic?

High significance means broad impact or urgency. Source trust reflects the average authority of outlets covering the story.

Significance5.3

Weighted from impact, urgency, coverage breadth, and topic sensitivity.

Source trust10.0

Average reliability level of outlets included in this topic.

Outlets1

Independent sources contributing to this topic cluster.

More outlets usually means a more confirmed developing story.

The report

The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose.

Read the full report at FDA ↗

Related in the knowledge graph

organizationDrug Administration organizationFDA organizationFDA Broadens Access organizationFood organizationOpioid Overdose. The U.S organizationOTC organizationOver-the-Counter Naloxone Nasal Spray organizationRextovy

Sources (1)

Avg source rating 10.0/10

FDA10